Please enable JavaScript.
Coggle requires JavaScript to display documents.
Weekly Commercial LT 23/02/18 (Weekly sell-out Voltaren (Voltadvance…
Weekly Commercial LT 23/02/18
Weekly sell-out OC
Polident far below expectation
Sensodyne and PDX higher than expectations but not enough to compensate Polident
Weekly sell-out Voltaren
Patches - gaining shares (but still negative on medicated)
Voltadvance decreasing when mkt is increasing
Not good performance in last 2 weeks
What the competitors are doing at POS?
gels: ok 2% and 1% suffering
Weekly Sell-out Rinazina
growing double digit and gaining MS for 4 weeks in a row
Respirabene not visible in the POS so far
Sell out canvass on Respirabene and Aquamarina starting 1 March
Syncro ATL/BTL needs improvement
Sales Febbraio
Bottom up -450k€ vs CMF (in linea con bottom up last week)
G2N (OOS, Credit blocks, CEV) higher than foreseen. Teoricamente è phasing
Difficoltà logistiche
4m€ ordini ancora da mandare in Phardis (ore 12.30)
Confidence to deliver everything before cutoff date
PDX complete protection launch
Watch out: classic rotating higher than Extra Fresh
Heads up for demand
Voltalgan OOS next 3 months (-0,3m£)
Rinazina drops OOS next 3 months (-0.1m£)
Sales Q1
-700K€ vs CMF
G2N (OOS, Credit blocks, CEV) higher than foreseen. Teoricamente è phasing